Company Performance Metrics
Sortina Pharma develops small molecule therapeutics that target sortilin for use in oncology and central nervous system indications. The company designs oral small molecule inhibitors that bind to sortilin and modulate progranulin and related pathways. Its lead oncology program focuses on a drug candidate for glioblastoma multiforme, with expansion
potential to other sortilin-driven cancers such as breast, pancreatic cancer, melanoma and colon cancer. In parallel, Sortina Pharma advances distinct small molecule structures intended for partnership in neurodegenerative diseases and other CNS conditions. The scientific portfolio is supported by a patent estate covering novel sortilin inhibitors and by collaborations with academic and clinical partners.
